Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

NCT07311993 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.

NCT NCT07311993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer
Lead sponsor
Cellectar Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 5, 2025
Completion date
July 31, 2029
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer